muscular atrophy


Also found in: Thesaurus, Medical, Legal, Encyclopedia, Wikipedia.
Translations

muscular atrophy

nMuskelatrophie f, → Muskelschwund m
References in periodicals archive ?
PTC Therapeutics announced that the FIREFISH study of RG7916 in Type 1 spinal muscular atrophy patients has transitioned into its pivotal phase with the dosing the first patient.
Motor delays that are most common include those due to cerebral palsy, Duchenne muscular dystrophy and spinal muscular atrophy.
M2 PHARMA-December 20, 2017-Biogen and Ionis Partner to Identify Novel Therapies for Treatment of Spinal Muscular Atrophy
Spinal muscular atrophy (SMA) is a genetic disorder which is clinically characterized by progressive muscle weakness and atrophy and is associated with the degeneration of spinal and lowers bulbar motor neurons.
In June 2017, SPINRAZA was approved for individuals with infantile-onset spinal muscular atrophy (SMA) by the Pharmaceuticals and Medical Devices Agency in Japan.
The European Medicines Agency (EMA) has recommended granting a marketing authorisation in the European Union (EU) for Spinraza (nusinersen) to treat patients with spinal muscular atrophy (SMA), a rare and often fatal genetic disease that causes muscle weakness and progressive loss of movement.
Global Markets Direct's, 'Spinal Muscular Atrophy (SMA) - Pipeline Review, H1 2016', provides an overview of the Spinal Muscular Atrophy (SMA) pipeline landscape.
The electro-diagnosis studies diagnosed Spinal Muscular Atrophy (SMA) in 31 cases (48.
MEMBERS of the Rotary Club of Warwick were given a presentation by Spinal Muscular Atrophy Support UK recently.
INTRODUCTION: DISCUSSION: Spinal muscular atrophy is characterized by degeneration of motor neuron in anterior cells and motor nuclei in brainstem.
July 1, 2015 -- New research has used pioneering stem cell techniques to better understand why certain cells are more at risk of degenerating in spinal muscular atrophy than others.
a biotechnology company focused on using gene therapy to transform the lives of patients with severe genetic and orphan diseases like Spinal Muscular Atrophy (SMA), today announced that the European Medicines Agency (EMA) has granted AveXis' wholly owned European subsidiary, AveXis EU Ltd.